NHS批准新的CAR T细胞疗法,以治疗剧烈的血癌,每年使大约600名病人受益。 NHS approves new CAR T-cell therapy for aggressive blood cancer, benefiting about 600 patients yearly.

英格兰国民保健体系已经批准了一个新的一次性的CAR T细胞治疗方案,治疗患有剧烈血癌的病人,特别是大型B细胞淋巴瘤,该细胞对初步治疗没有反应。 The NHS in England has approved a new, one-time CAR T-cell therapy for patients with aggressive blood cancer, specifically large B-cell lymphoma, which hasn't responded to initial treatments. 治疗(Lisogabtagene maraleucel)涉及重新规划病人的免疫细胞以对抗癌症,表明在无进展生存方面有显著改善。 The treatment, lisocabtagene maraleucel, involves reprogramming the patient's immune cells to fight cancer, demonstrating significant improvement in progression-free survival. 这项决定每年可能使大约600名病人受益。 This decision could benefit around 600 patients annually.